<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1708">
  <stage>Registered</stage>
  <submitdate>10/10/2007</submitdate>
  <approvaldate>10/10/2007</approvaldate>
  <nctid>NCT00542880</nctid>
  <trial_identification>
    <studytitle>Evaluation of Onset of Effect in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD) Treated With Symbicort® Compared to Seretide®</studytitle>
    <scientifictitle>A Double-blind, Randomised, Cross-over, Multi-centre Study, to Evaluate Onset of Effect in the Morning in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD) Treated With Symbicort®Turbuhaler® 320/9 µg, Compared With Seretide® Diskus® 50/500 µg, Both Given as One Inhalation Twice Daily for One Week Each.</scientifictitle>
    <utrn />
    <trialacronym>SPEED</trialacronym>
    <secondaryid>D5892C00016</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Chronic Obstructive Pulmonary Disease (COPD)</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Chronic obstructive pulmonary disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Symbicort Turbuhaler (budesonide/formoterol) 320/9 µg
Treatment: drugs - Seretide Diskus (salmeterol/fluticasone) 50/500 µg

Experimental: Symbicort Turbuhaler First, then Seretide Diskus - Symbicort Turbuhaler (budesonide/formoterol) 320/9 µg First, then Seretide Diskus (salmeterol/fluticasone) 50/500 µg

Experimental: Seretide Diskus First, then Symbicort Turbuhaler - Seretide Diskus (salmeterol/fluticasone) 50/500 µg First, then Symbicort Turbuhaler (budesonide/formoterol) 320/9 µg


Treatment: drugs: Symbicort Turbuhaler (budesonide/formoterol) 320/9 µg


Treatment: drugs: Seretide Diskus (salmeterol/fluticasone) 50/500 µg


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Peak Expiratory Flow (PEF) 5 Minutes After Morning Dose - The change from baseline in PEF was calculated using the average over baseline (the last 7 days of run-in and washout period respectively), and all days of treatment, with baseline as covariate.</outcome>
      <timepoint>Baseline (daily records during run-in, and washout) and daily records during the treatment period of 7 days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>PEF Before Morning Dose - The change from baseline was calculated using the average over baseline (the last 7 days of run-in and washout period respectively), and over all days of treatment, with baseline as covariate.</outcome>
      <timepoint>Baseline (daily records during run-in, and washout) and daily records during the treatment period of 7 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PEF 15 Minutes After Morning Dose - The change from baseline was calculated using the average over baseline (the last 7 days of run-in and washout period respectively), and over all days of treatment, with baseline as covariate.</outcome>
      <timepoint>Baseline (daily records during run-in, and washout) and daily records during the treatment period of 7 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PEF Before Evening Dose - The change from baseline was calculated using the average over baseline (the last 7 days of run-in and washout period respectively), and over all days of treatment, with baseline as covariate.</outcome>
      <timepoint>Baseline (daily records during run-in, and washout) and daily records during the treatment period of 7 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Forced Expiratory Volume in 1 Second (FEV1) Before Morning Dose - The change from baseline was calculated using the average over baseline (the last 7 days of run-in and washout period respectively), and over all days of treatment, with baseline as covariate.</outcome>
      <timepoint>Baseline (daily records during run-in, and washout) and daily records during the treatment period of 7 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>FEV1 15 Minutes After Morning Dose - The change from baseline was calculated using the average over baseline (the last 7 days of run-in and washout period respectively), and over all days of treatment, with baseline as covariate.</outcome>
      <timepoint>Baseline (daily records during run-in, and washout) and daily records during the treatment period of 7 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>FEV1 Before Evening Dose - The change from baseline was calculated using the average over baseline (the last 7 days of run-in and washout period respectively), and over all days of treatment, with baseline as covariate.</outcome>
      <timepoint>Baseline (daily records during run-in, and washout) and daily records during the treatment period of 7 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in PEF From Before Dose to 5 Minutes After Dose in the Morning - The change from pre-dose was calculated using the average over baseline (the last 7 days of run-in and washout period respectively), and over all days of treatment, with pre-dose run-in/washout as covariate.</outcome>
      <timepoint>Baseline (daily records during run-in, and washout) and daily records during the treatment period of 7 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in PEF From Before Dose to 15 Minutes After Dose in the Morning - The change from pre-dose was calculated using the average over baseline (the last 7 days of run-in and washout period respectively), and over all days of treatment, with mean pre-dose run-in/washout as covariate.</outcome>
      <timepoint>Baseline (daily records during run-in, and washout) and daily records during the treatment period of 7 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in FEV1from Before Dose to 5 Minutes After Dose in the Morning - The change from pre-dose was calculated using the average over baseline (the last 7 days of run-in and washout period respectively), and over all days of treatment, with mean pre-dose run-in/washout as covariate.</outcome>
      <timepoint>Baseline (daily records during run-in, and washout) and daily records during the treatment period of 7 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in FEV1 From Before Dose to 15 Minutes After Dose in the Morning - The change from pre-dose was calculated using the average over baseline (the last 7 days of run-in and washout period respectively), and over all days of treatment, with mean pre-dose run-in/washout as covariate.</outcome>
      <timepoint>Baseline (daily records during run-in, and washout) and daily records during the treatment period of 7 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in FEV1 From Before Dose to 5 Minutes After Dose at the Clinic - The change from pre-dose was calculated using the pre-dose baseline value (run-in and washout period respectively), and pre-dose value at day 1, with pre-dose run-in/washout as covariate.</outcome>
      <timepoint>Baseline (run-in, and washout) and day 1 of treatment period</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in Forced Vital Capacity (FVC) From Before Dose to5 Minutes After Dose at the Clinic - The change from pre-dose was calculated using the pre-dose baseline value (run-in and washout period respectively), and pre-dose value at day 1, with pre-dose run-in/washout as covariate.</outcome>
      <timepoint>Baseline (run-in, and washout) and day 1 of treatment period</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Capacity of Daily Living in the Morning (CDLM) (Change From Pre to End of Treatment) - The change from baseline was calculated using the average over baseline (the last 7 days of run-in and washout period respectively), and over all days of treatment, with baseline as covariate. Score scale 0 - 5 with 0=worst and 5 = best.</outcome>
      <timepoint>Baseline (daily records during run-in, and washout) and daily records during the treatment period of 7 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Difficulty in Getting Out From Bed (MASQ) (Change From Pre to End of Treatment) - The change from baseline was calculated using the average over baseline (the last 7 days of run-in and washout period respectively), and over all days of treatment, with baseline as covariate. Score scale 0 - 5 with 0=worst and 5 = best.</outcome>
      <timepoint>Baseline (daily records during run-in, and washout) and daily records during the treatment period of 7 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The Clinical Chronic Obstructive Pulmonary Disease (COPD) Questionnaire (Change From Pre to End of Treatment) - The change from baseline was calculated using the average over baseline (the last 7 days of run-in and washout period respectively), and over all days of treatment, with baseline as covariate. Score scale 0 - 6 with 0=worst and 6 = best.</outcome>
      <timepoint>Baseline (daily records during run-in, and washout) and daily records during the treatment period of 7 days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Outpatient, female or male aged =40 years, diagnosis of COPD with symptoms for at
             least 2 years

          -  FEV1 =50% of predicted normal value, pre-bronchodilator, FEV1/VC &lt;70%

          -  Pre-bronchodilator</inclusivecriteria>
    <inclusiveminage>40</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Current respiratory tract disorder other than COPD

          -  History of asthma or rhinitis

          -  Significant or unstable cardiovascular disorder</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/09/2007</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>442</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/08/2008</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,SA,VIC,WA</recruitmentstate>
    <hospital>Research Site - Concord</hospital>
    <hospital>Research Site - Adelaide</hospital>
    <hospital>Research Site - Daw Park</hospital>
    <hospital>Research Site - Woodville South</hospital>
    <hospital>Research Site - Melbourne</hospital>
    <hospital>Research Site - Parkville</hospital>
    <hospital>Research Site - Nedlands</hospital>
    <postcode> - Concord</postcode>
    <postcode> - Adelaide</postcode>
    <postcode> - Daw Park</postcode>
    <postcode> - Woodville South</postcode>
    <postcode> - Melbourne</postcode>
    <postcode> - Parkville</postcode>
    <postcode> - Nedlands</postcode>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Buenos Aires</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Tucuman</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Ciudad Autonoma de Bs. As.</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Ciudad de Buenos Aires</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Jambes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Malmedy</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Montigny-le-tilleul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Brasil</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>MG</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>PE</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>RJ</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>RS</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Santa Catarina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>SP</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Rio de Janeiro</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Aalborg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Alborg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Hellerup</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Hvidovre</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Kobenhavn Nv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Odense C</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Rodovre</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Silkeborg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Erfurt</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Leipzig</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Marburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Andhra Pradesh</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Karnataka</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Rajasthan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Coimbatore</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Noida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Philippines</country>
      <state>Manila</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Philippines</country>
      <state>Quezon City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Kent</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Lanarkshire</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>N. Ireland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Northern Ireland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>South Glamorgan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Vale of Glamorgan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Wiltshire</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Airdrie</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Birmingham</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Blantyre</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Bolton</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Carrickfergus</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Chesterfield</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Coventry</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Hamilton</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>AstraZeneca</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study is to assess the effects with two different inhaled respiratory medications with
      regards to improvement of lung function, symptoms and morning activities.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00542880</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Tomas Andersson, MD</name>
      <address>AstraZeneca</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>